Literature DB >> 16267264

Role of VAD in the initial treatment of multiple myeloma.

Steven W Lane, Devinder Gill, Peter N Mollee, S Vincent Rajkumar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16267264     DOI： 10.1182/blood-2005-07-2610

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

Review 1.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

Review 2.  Emerging therapies for multiple myeloma.

Authors:  Klaus Podar; Yu-Tzu Tai; Teru Hideshima; Sonia Vallet; Paul G Richardson; Kenneth C Anderson
Journal:  Expert Opin Emerg Drugs       Date:  2009-03       Impact factor: 4.191

3.  Is there a role for 'modified VAD' in the treatment of multiple myeloma?

Authors:  A Agazzi; S Sammassimo; D Laszlo; Sj Liptrott; R Cascio; A Alietti; C Rabascio; P Mancuso; G Pruneri; G Martinelli
Journal:  Ecancermedicalscience       Date:  2009-06-04

4.  The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis.

Authors:  Gan-Lin He; Duo-Rong Xu; Wai-Yi Zou; Sui-Zhi He; Juan Li
Journal:  Biomed Res Int       Date:  2018-11-11       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.